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Context: Observational studies suggest that variations in normal range thyroid function are 
associated with cardiovascular diseases. However, it remains to be determined whether these 
associations are causal or not.
Objective: To test whether genetically determined variation in normal range thyroid function is 
causally associated with the risk of stroke and coronary artery disease (CAD) and investigate via 
which pathways these relations may be mediated.
Design, Setting, and Participants: Mendelian randomization analyses for stroke and CAD using 
genetic instruments associated with normal range thyrotropin (TSH) and free thyroxine levels or 
Hashimoto’s thyroiditis and Graves’ disease. The potential mediating role of known stroke and 
CAD risk factors was examined. Publicly available summary statistics data were used.
Main Outcome Measures: Stroke or CAD risk per genetically predicted increase in TSH or FT4 
levels.
Results: A 1 standard deviation increase in TSH was associated with a 5% decrease in the risk 
of stroke (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.91-0.99; P = 0.008). Multivariable 
MR analyses indicated that this effect is mainly mediated via atrial fibrillation. MR analyses did 
not show a causal association between normal range thyroid function and CAD. Secondary 
analyses showed a causal relationship between Hashimoto’s thyroiditis and a 7% increased risk 
of CAD (OR, 1.07; 95% CI, 1.01-1.13; P = 0.026), which was mainly mediated via body mass index.
Conclusion: These results provide important new insights into the causal relationships and 
mediating pathways between thyroid function, stroke, and CAD. We identify variation in 
*These authors contributed equally to this work.
Abbreviations: AF, atrial fibrillation; BMA, Bayesian model averaging; BMI, body mass 
index; BP, blood pressure; CAD, coronary artery disease; CI, confidence interval; CVD, 
cardiovascular disorder; FT4, free thyroxine; GWAS, genome-wide association studies; 
IVW, inverse-variance-weighted; MR, Mendelian randomization; OR, odds ratio; SD, 
standard deviation; SNP, single nucleotide polymorphism; T2D, type diabetes; TSH, 
thyrotropin.
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normal range thyroid function and Hashimoto’s thyroiditis as risk factors for stroke and CAD, 
respectively. (J Clin Endocrinol Metab XX: 0–0, 2020)
Key Words:  Mendelian randomization, thyroid function, TSH, stroke, coronary artery disease, 
mediation
D espite the undeniable progress in prevention and treatment in the past 2 decades, cardiovascular 
disorders (CVDs) remain the leading cause of mortality 
worldwide (1). Whereas smoking, hypertension, dia-
betes, obesity, and dyslipidaemia are the major modi-
fiable cardiovascular risk factors (2), observational 
studies have demonstrated that also overt and subclin-
ical thyroid dysfunction are associated with a higher 
risk of CVD (3-6). More recently, several population-
based studies showed that even higher free thyroxine 
(FT4) levels within the normal range are associated 
with an increased risk of CVD, including atheroscler-
otic disease and stroke (7-10). Bano et al estimated that 
this culminates in an increased risk of atherosclerotic 
cardiovascular mortality in euthyroid individuals, with 
a hazard ratio of 2.4 per 1 ng/dL increase in FT4 levels 
and a hazard ratio of 0.92 per 1 log thyrotropin (TSH) 
increase in TSH levels (10).
Observational studies are typically prone to biases in 
study design, residual confounding, and reverse caus-
ality (11). It is therefore unclear if the observed associ-
ations between mild variations in thyroid function and 
atherosclerotic diseases are causal or not, which is a key 
question that needs to be resolved first. Mendelian ran-
domization (MR) is an approach that can provide such 
information on causality (12). MR evaluates the effect 
of an exposure (eg, thyroid function) on an outcome 
(eg, CVD) using genetic variants associated with the 
exposure as instruments (13). MR draws from the fact 
that genetic variants segregate randomly from parents 
to offspring, which is comparable to the randomiza-
tion used in clinical trials. As approximately 65% of 
the total variance in TSH and FT4 levels is determined 
by genetic factors (14), there are good grounds for MR 
studies on thyroid function and various outcomes. 
A previous MR study suggested no causal association 
between thyroid function and the risk of ischemic heart 
disease (15). However, this study had limited statistical 
power as it used a small number of genetic variants as 
instruments, which only explained 5.6% of the vari-
ance for TSH and 2.3% of the variance for FT4 levels 
(16). Other MR studies on thyroid function and CVD 
did not use the largest available genome-wide associ-
ation studies (GWAS) for CVD (17) or any stroke (18). 
The ThyroidOmics Consortium performed the largest 
meta-analysis of GWAS on thyroid function in more 
than 72  000 participants, which more than doubled 
the number of genetic variants associated with thyroid 
function (19, 20). These findings have now paved the 
way to conduct well-powered MR studies to test the 
causality of the observed associations between thyroid 
function and CVD. In the current study, we performed 
2-sample MR to investigate the effects of thyroid func-
tion on CAD and stroke, using the previously mentioned 
thyroid GWAS data, as well as data from the 2 largest 
GWAS on CAD and stroke (17, 18). Next to normal 
range thyroid function, MR studies on Hashimoto’s 
thyroiditis and Graves’ disease are presented as sec-
ondary analyses, thereby covering the entire spectrum 
of thyroid (dys)function. Finally, multivariable MR ana-
lyses were performed to investigate the pathophysio-
logical mechanisms underlying the causal associations.
Materials and Methods
Primary analyses tested whether associations between vari-
ation in normal range thyroid function assessed via TSH and 
FT4 levels and the risk of stroke or CAD are causal. Secondary 
analyses tested whether thyroid dysfunction, including 
Hashimoto’s thyroiditis and Graves’ disease, is causally asso-
ciated with stroke or CAD. When we observed evidence for 
causality, we further assessed the role of potential mediators.
All P values are 2-sided, and statistical significance was de-
fined as a P value of 0.0125, corresponding to a Bonferroni 
correction of 4 tests for the primary analyses (2 exposures 
[TSH and FT4] and 2 outcomes [CAD and stroke]) as the ex-
posures included in the secondary analyses are strongly re-
lated to TSH and FT4 levels.
Genetic variants used as instruments
For normal range TSH and FT4 levels, we used 55 and 29 
single nucleotide polymorphisms (SNPs) associated at a genome-
wide significant level (P< 5 × 10–8). One variant (rs8176645) 
in the ABO gene was excluded because of its pleiotropic ef-
fects on multiple traits. In order to cover the entire spectrum 
of thyroid (dys)function, we also assessed the effect of hypo-
thyroidism and hyperthyroidism on stroke and CAD risk. For 
this reason, we also performed a literature search for genetic 
variants associated with Hashimoto’s thyroiditis and Graves’ 
disease, resulting in 20 variants and 49 variants, respectively. 
We included common genetic variants (ie, variants with minor 
allele frequency > 5%) associated with Hashimoto’s thyroiditis 
or Graves’ disease in case-control studies with a sample size 
of > 200 cases and controls each, at a significant level (P < 0.05) 
after a multiple testing correction for a number of variants 
tested in each study. Variants within the human leukocyte 
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antigen region associated in non-Caucasian populations were 
excluded and tagging SNPs for human leukocyte antigen al-
leles/haplotypes associated with Hashimoto’s thyroiditis and 
Graves’ disease in Caucasian populations were added, if avail-
able. Their associations with the corresponding thyroid disease 
were derived from UK Biobank, which recruited more than 
500 000 individuals across Great Britain from 2006 through 
2010 (21). Hashimoto’s thyroiditis and Graves’ disease were 
defined using hospital record data: International Classification 
of Diseases (ICD10) codes for Hashimoto’s thyroiditis were 
E03.8, E03.9, and E06.3 and for Graves’ disease were E05.0, 
E05.8, and E05.9.
Additional sensitivity analyses, as described below, were 
performed in order to address pleiotropy and heterogeneity.
Two-sample MR
We performed 2-sample MR analyses by using summary 
genetic data from the largest GWAS studies available for 
normal range thyroid function (19), CAD (17), and stroke 
(18). Genetic variants associated with TSH and FT4 levels were 
derived from Teumer et al (19). In this study, TSH and FT4 
values were collected at a single time point in all cohorts, and 
a normal thyroid function was defined as a TSH level within 
the reference ranges, which are listed in Supplemental Table 1 
of the respective manuscript (19). A 1 standard deviation (SD) 
increase in the genetically determined values of TSH corres-
ponds to 0.8 mIU/L, and a 1 SD increase in genetically de-
termined FT4 corresponds to 0.2  ng/dL
16. CAD data were 
derived from the largest GWAS meta-analysis by Van Harst 
et al, involving 122 733 CAD cases and 424 528 controls (17). 
Stroke data were derived from Malik et al, involving 67 162 
cases and 454 450 controls (18).
Two-sample MR was performed using the inverse-
variance-weighted (IVW) (22) method, which is the gold 
standard for MR analyses. To further elucidate the role of 
pleiotropic effects and heterogeneity, we performed add-
itional sensitivity analyses that are presented in the supple-
mentary material; All supplementary material and figures are 
located in a digital research materials repository (23).
Multivariable MR analyses
When MR showed a causal relationship between thy-
roid (dys)function and CAD or stroke, multivariable MR 
analyses were performed to evaluate the role of known risk 
factors for stroke or CAD. These risk factors included body 
mass index (BMI); heart rate; blood pressure (BP); systolic 
BP and diastolic BP; mean arterial pressure; pulse pressure; 
lipid traits including total cholesterol, low-density lipoprotein, 
high-density lipoprotein, and triglycerides as well as type 2 
diabetes (T2D) and atrial fibrillation (AF). Educational attain-
ment was assessed by age based on when full-time education 
was completed, which serves as an indicator of socioeconomic 
status and is inversely associated with CAD risk. In these 
analyses, the proportion of the effect mediated by the tested 
factor was evaluated by the change in the total effect of the 
genetically determined exposure on the outcomes (24). T2D 
data were derived from the DIAGRAM consortium (25); 
high-density lipoprotein, low-density lipoprotein, total chol-
esterol, and triglyceride levels were obtained from the GLGC 
(26) and ENGAGE consortia (27); and anthropometric 
traits including BMI from the GIANT consortium (28). BP 
traits were derived from International Consortium for Blood 
Pressure (29), AF data from Nielsen et al (30), and heart rate 
data from Verweij, et al (31). Finally, data on which age an 
individual completed full-time education were derived from 
publically available summary statistics (32).
No ethical approval was required as all data were extracted 
from publicly available summary data.
Power calculations
To estimate the power of our study, we calculated the min-
imally detectable odds ratio (OR) of the outcome variable 
(CAD and stroke) per SD of the exposure variables (TSH and 
FT4 levels) using a noncentrality parameter-based approach 
(33), implemented in a publicly available mRnd web tool 
(power = 0.8, α = 0.05) in our study. Proportion of total vari-
ance in TSH and FT4 levels explained by the genetic variants 
used as instruments was 9.4% and 4.8%, respectively (19).
Statistical analyses were performed using R version 3.5.1.
Results
Normal range TSH and FT4 levels
MR analyses showed a significant association be-
tween higher TSH levels within the normal range and a 
lower risk of stroke (OR, 0.95; 95% confidence interval 
[CI], 0.91-0.99; P = 0.008 per 1 SD increase in TSH 
levels). There was no evidence of directional pleiotropy 
(Egger intercept = 1.06e-5, standard error = 0.003) 
(Fig.  1A). As no single method controls for all statis-
tical properties that may affect MR estimates, we ap-
plied additional MR approaches that yielded similar 
results. Direction and effect sizes remained similar when 
restricting the analyses to Europeans only.
There was no evidence for an association between 
normal range FT4 levels and the risk of stroke (OR, 
0.97; 95% CI, 0.89-1.06; P = 0.50 per 1 SD increase in 
FT4 levels) (Fig. 1A).
For CAD, no causal associations were detected with 
normal range TSH (OR, 1.01; 95% CI, 0.96-1.05; 
P = 0.80 per 1 SD increase in TSH levels) or FT4 levels 
(OR, 0.99; 95% CI, 0.94-1.04; P = 0.66 per 1SD in FT4 
levels) using IVW. Sensitivity analyses with other methods 
yielded similar results without signs of pleiotropy (Fig. 1B).
Secondary analyses
Hypothyroidism (Hashimoto’s thyroiditis).  MR 
analyses did not show a causal effect of Hashimoto’s 
thyroiditis on the risk of stroke. Hashimoto’s thyroiditis 
was causally associated with an increased risk of CAD 
(OR, 1.07; 95% CI, 1.01-1.13; P = 0.026). This was con-
firmed by other methods, while there was no evidence for 
pleiotropic effects; All supplementary material and figures 
are located in a digital research materials repository (23).
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Hyperthyroidism (Graves’ disease). No causal asso-
ciations between Graves’ disease and stroke (OR, 0.99; 
95% CI, 0.96-1.02; P = 0.37) or CAD (OR, 1.01; 95% 
CI, 0.98-1.03; P= 0.49) were detected.
Multivariable MR analyses
TSH and stroke risk. We assessed the role of potential 
stroke risk factors that might mediate the observed as-
sociation between normal range TSH levels and stroke. 
These analyses identified AF as a potential mediator as 
the association between TSH levels and the risk of stroke 
disappeared after adjustment for AF (OR, 1.00; 95% 
CI, 0.95-1.06; P = 0.86) (Fig.  2). Taking into account 
the genetic effect of lipid levels did not affect the effect 
of TSH on stroke risk and MR-Bayesian model aver-
aging (BMA) did not rank lipids as an important medi-
ator; All supplementary material and figures are located 
in a digital research materials repository (23).
Further multivariable MR analyses showed that the 
association between TSH and AF is not mediated by a 
number of known AF risk factors including BP, lipids, 
CAD, or T2D.
As the results presented above suggested that AF was a 
putative mediator in the association between TSH levels 
and stroke, we used the MR-BMA method to further cor-
roborate this finding. MR-BMA can detect true causal 
risk factors even when the candidate risk factors are 
highly correlated (34). This analysis confirmed that AF 
was the top mediating factor. Further inspection of the 
models indicated 2 variants (rs74804879, rs17477923) 
as influential points. AF remained the top risk factor after 
exclusion of these variants, supporting the robustness of 
our findings; All supplementary material and figures are 
located in a digital research materials repository (23).
Hashimoto’s thyroiditis and CAD risk. Multivariable 
MR analyses indicated that the effect of Hashimoto’s 
thyroiditis on CAD may be mediated via BMI (Fig. 3). 
Additional analyses (MR-MBA method) were per-
formed in order to get a more robust overview of the 
role of potential mediators after excluding potential 
pleiotropic variants. The top 2 risk factors identified 
were heart rate and BMI, as presented in Supplementary 
Table 8, All supplementary material and figures are lo-
cated in a digital research materials repository (23).
Discussion
In this study, we performed the largest MR analyses of 
thyroid function on stroke and CAD risk to date. MR 
can provide important information on causality when 
randomized controlled trials are not feasible or unavail-
able. MR uses genotypes that are generally not suscep-
tible to reverse causation or confounding. This provides a 
cost-effective approach to prioritize potential targets for 
disease prediction and/or prevention. Our results show 
that higher TSH levels within the normal range are associ-
ated with a lower risk of stroke and that this effect is me-
diated by a lower risk of AF. Furthermore, we show that 
Hashimoto’s thyroiditis leads to a higher risk of CAD.
Association between high normal range TSH 
levels and lower risk of stroke is mediated by a 
decreased risk of AF
In 2016, a multicenter study including 43 598 parti-
cipants investigated the association between variation in 
normal range thyroid function and stroke risk (9). This 
study showed that higher TSH levels within the normal 
range were associated with a decreased risk of stroke, 
while higher FT4 levels within the normal range were as-
sociated with an increased risk of stroke. In an attempt 
to identify the responsible pathophysiological pathways, 
the authors tested various traditional cardiovascular risk 
factors, including systolic BP, total cholesterol levels, 
smoking status, and T2D (9) but could not identify a 
responsible mediator. More recently, an MR study also 
Figure 1. Two-sample Mendelian randomization analyses. Estimates of the effect of TSH and FT4 levels on stroke (A) and coronary artery disease 
(B). Effect estimates represent the ORs (95% CI). CAD, coronary artery disease; CI, confidence interval; FT4, free thyroxine; IVW, inverse-variance-
weighted; OR, odds ratio, TSH, thyrotropin. 
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reported a suggestive association of genetically decreased 
TSH levels with a higher risk of the cardiometabolic sub-
types of stroke (35). In the current study, we also assessed 
causality in the observed associations between normal 
range thyroid function and stroke but used the largest 
available datasets for normal range thyroid function and 
any stroke type (18) to improve on power compared 
with the previous studies (35). We demonstrate that high-
normal TSH levels are associated with a decreased risk of 
stroke, which we show to be mediated by a decreased risk 
of AF. This is both pathophysiologically plausible and in 
line with the results of observational studies showing 
that AF is a major risk factor for stroke, increasing stroke 
risk up to 5-fold (36). Our findings are also in line with 
various studies showing that a high-normal thyroid func-
tion is associated with an increased risk of AF (37) and 
that participants with a genetically predicted higher TSH 
level have a lower risk of AF (38). While multiple patho-
physiological pathways could theoretically be respon-
sible for the effect of variations in normal range thyroid 
function on stroke, we for the first time demonstrated 
that AF is the key mediator. In addition, this also showed 
that multivariable MR analyses can reveal pathophysio-
logical mechanisms underlying the effects of variation in 
thyroid function.
The absence of causal associations between FT4 
levels and the risk of stroke in our study is not conclu-
sive as it may be due to the fact that the genetic variants 
Figure 2. Multivariable MR analysis of the effect of TSH levels (per SD) on stroke after adjusting for the genetic effect of possible mediators. 
AF, atrial fibrillation; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; EA, educational attainment; HDL, high-density 
lipoprotein; HR, heart rate; LDL, low-density lipoprotein; MAP, mean arterial pressure; MR-IVW, Mendelian randomization inverse-variance-
weighted; OR, odds ratio; PP, pulse pressure; SBP, systolic blood pressure; SD, standard deviation; T2D, type 2 diabetes; T2DadjBMI, T2D adjusted 
for BMI; TC, total cholesterol; TG, triglycerides; TSH, thyrotropin.
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used as instruments explained less variance in FT4 than 
in TSH levels (ie, 4.8% and 9.4%, respectively) (19).
Therefore, our study was better powered for TSH than 
for FT4. Therefore, if there was a causal effect of normal 
range variation in FT4 levels on stroke risk, it would be 
smaller than what our study is powered to detect.
MR analyses do not support a causal association 
between normal range thyroid function and the 
risk of CAD
Bano et  al have shown that variation in thyroid 
hormone levels within the normal range are associated 
with subclinical atherosclerosis as assessed by a coronary 
artery calcification score and the overall risk of adverse 
atherosclerotic cardiovascular events, including fatal 
and nonfatal myocardial infarction, other CAD mor-
tality, and stroke (10). While several other population-
based studies have not found associations between 
normal range thyroid function and the risk of CAD 
only, most of these studies did show associations with 
increased CAD mortality (8, 39-41). While these studies 
suggest an important relation between thyroid function 
and CAD, observational studies are typically prone to 
various sources of bias, including biases in study de-
sign, reverse causality, and residual confounding (11). 
Previous MR studies did not find any causal association 
between thyroid function and CAD (35). In this study, 
we further increased power compared with previous 
efforts by using the biggest available dataset for CAD, 
and we did not find evidence for a causal association 
between normal range thyroid function and the risk of 
CAD either. However, we can obviously not exclude 
that thyroid function affects CAD risk, but the effect is 
smaller than what our study can detect. Furthermore, 
an effect of minor variation in thyroid function on CAD 
risk might be mediated by other factors such as hyper-
tension and dyslipidemia. These cardiovascular risk fac-
tors are currently widely recognized and treated, which 
therefore might have diluted the potential cause-and-
effect relationship between thyroid function and the 
CAD risk in the studied populations.
Hashimoto’s thyroiditis and CAD risk
In observational studies, both overt and subclinical 
hypothyroidism have been associated with an increased 
risk of atherosclerosis and adverse cardiovascular events, 
including CAD (3, 4, 42). We focused our analyses on 
Hashimoto disease as this is the most common cause 
of hypothyroidism. While our study demonstrates for 
the first time a causal association between Hashimoto’s 
thyroiditis and CAD, it is not clear whether this effect is 
attributed solely to a low thyroid function or to auto-
immunity in general, since many observational studies 
suggest an increased risk of atherosclerosis and adverse 
Figure 3. Multivariable MR analysis of the effect of Hashimoto disease on CAD after adjusting for the genetic effect of possible mediators. AF, 
atrial fibrillation; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; EA, educational attainment; HDL, high-density 
lipoprotein; HR, heart rate; LDL, low-density lipoprotein; MAP, mean arterial pressure; MR-IVW, Mendelian randomization inverse-variance-
weighted; OR, odds ratio; PP, pulse pressure; SBP, systolic blood pressure; SD, standard deviation; T2D, type 2 diabetes; T2DadjBMI, T2D adjusted 
for BMI; TC, total cholesterol; TG, triglycerides; TSH, thyrotropin.
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cardiovascular events in patients with other autoimmune 
disorders (43). Therefore, future studies are needed to 
further clarify the underlying pathophysiological rela-
tionship between Hashimoto’s thyroiditis and CAD.
Strengths and limitations of the study
In order to increase the power of our study, we used 
summary data from the largest available GWAS on thy-
roid function recently published by the ThyroidOmics 
Consortium, which more than doubled the number of 
variants associated with TSH and FT4 levels (19, 20). 
This significantly increased our statistical power com-
pared with the previous published MR study on thy-
roid function and CVD by Zhao et al. (15) Furthermore, 
we used data from the 2 largest available GWAS meta-
analyses on the tested cardiovascular outcomes, both 
including more than 500  000 participants (17, 18). 
This included data for any stroke type from the lar-
gest transethnic meta-analysis (21), which significantly 
increased the sample size of our study compared with 
an MR study previously performed by Larsson et  al 
(35). Also, the sample size of Graves’  disease cases in 
UK Biobank was limited. This might have led to less 
precise effect estimates, resulting in less power to de-
tect a causal association in our secondary analyses on 
Graves’ disease.
Given the relatively large number of variants with 
unclear physiological function included in the MR 
analyses, it is possible that some of them may confer 
pleiotropic effects. However, the use of multiple vari-
ants associated with TSH and FT4 levels should reduce 
the impact of individual SNPs associated with the out-
come through alternative pathways (13). Moreover, we 
performed sensitivity analyses excluding potentially 
pleiotropic variants, which did not change our results. 
Finally, the IVW method can lead to moderately biased 
estimates for binary outcomes (44). To address this 
issue, we applied different MR approaches, which in 
most cases led to consistent results.
In conclusion, these results show that variation 
in normal range thyroid function and Hashimoto’s 
thyroiditis are causally associated with stroke and CAD 
and provide insights into the underlying pathophysio-
logical pathways involved. The association between 
variation in normal range thyroid function and stroke 
suggests that the use of classical population-based ref-
erence ranges might not be optimal for optimizing an 
individual’s disease risk. Future studies should inves-
tigate whether a disease risk-oriented range would 
be more beneficial, which should also take the risk of 
various other thyroid dysfunction-related complications 
into account.
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